CHDI
Listed here are over 1000 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
To TM, Exuzides A, Abbass IM, Patel AM, Ta JT, Surinach A, Fuller RLM, Luo J
Health care resource utilization and costs among individuals with vs without Huntington disease in a US population
J Manag Care Spec Pharm
November 1, 2022
28 (11) :1228-1239
28 (11) :1228-1239
PMID: 36282937
Marchionini DM, Liu JP, Ambesi-Impiombato A, Kerker K, Cirillo K, Bansal M, Mushlin R, Brunner D, Ramboz S, Kwan M, Kuhlbrodt K, Tillack K, Peters F, Rauhala L, Obenauer J, Greene JR, Hartl C, Khetarpal V, Lager B, Rosinski J, Aaronson J, Alam M, Signer E, Muñoz-Sanjuán I, Howland D, Zeitlin SO
Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model
Wang N, Langfelder P, Stricos M, Ramanathan L, Richman JB, Vaca R, Plascencia M, Gu X, Zhang S, Tamai TK, Zhang L, Gao F, Ouk K, Lu X, Ivanov LV, Vogt TF, Lu QR, Morton AJ, Colwell CS, Aaronson JS, Rosinski J, Horvath S, Yang XW
Mapping brain gene coexpression in daytime transcriptomes unveils diurnal molecular networks and deciphers perturbation gene signatures
Ly S, Didiot MC, Ferguson CM, Coles AH, Miller R, Chase K, Echeverria D, Wang F, Sadri-Vakili G, Aronin N, Khvorova A
Mutant huntingtin messenger RNA forms neuronal nuclear clusters in rodent and human brains
Dawson J, Baine-Savanhu FK, Ciosi M, Maxwell A, Monckton DG, Krause A
A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry
Lowe AJ, Rodrigues FB, Arridge M, De Vita E, Johnson EB, Scahill RI, Byrne LM, Tortelli R, Heslegrave A, Zetterberg H, Wild EJ
Longitudinal evaluation of proton magnetic resonance spectroscopy metabolites as biomarkers in Huntington's disease
Shin JW, Hong EP, Park SS, Choi DE, Seong IS, Whittaker MN, Kleinstiver BP, Chen RZ, Lee JM
Allele-specific silencing of the gain-of-function mutation in Huntington's disease using CRISPR-Cas9
Conroy F, Miller R, Alterman JF, Hassler MR, Echeverria D, Godinho BMDC, Knox EG, Sapp E, Sousa J, Yamada K, Mahmood F, Boudi A, Kegel-Gleason K, DiFiglia M, Aronin N, Khvorova A, Pfister EL
Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models
Bertoglio D, Zajicek F, Lombaerde S, Miranda A, Stroobants S, Wang Y, Dominguez C, Munoz-Sanjuan I, Bard J, Liu L, Verhaeghe J, Staelens S
Validation, kinetic modeling, and test-retest reproducibility of [18F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice
Maibach HT, Brownstein MJ, Hersch SM, Anderson KE, Itzkowitz DE, Damiano EM, Simon NG
The vasopressin 1a receptor antagonist SRX246 reduces aggressive behavior in Huntington's disease
Macabuag N, Esmieu W, Breccia P, Jarvis R, Blackaby W, Lazari O, Urbonas L, Eznarriaga M, Williams R, Strijbosch A, Van de Bospoort R, Matthews K, Clissold C, Ladduwahetty T, Vater H, Heaphy P, Stafford DG, Wang HJ, Mangette JE, McAllister G, Beaumont V, Vogt TF, Wilkinson HA, Doherty EM, Dominguez C
Developing HDAC4-selective protein degraders to investigate the role of HDAC4 in Huntington's disease pathology
Randazzo P, Sinisi R, Gornati D, Bertuolo S, Bencheva L, De Matteo M, Nibbio M, Monteagudo E, Turcano L, Bianconi V, Peruzzi G, Summa V, Bresciani A, Mozzetta C, Di Fabio R
Identification and in vitro characterization of a new series of potent and highly selective G9a inhibitors as novel anti-fibroadipogenic agents
Shin JW, Hong EP, Park SS, Choi DE, Zeng S, Chen RZ, Lee JM
PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington's disease
Neueder A, Kojer K, Hering T, Lavery DJ, Chen J, Birth N, Hallitsch J, Trautmann S, Parker J, Flower M, Sethi H, Haider S, Lee JM, Tabrizi SJ, Orth M
Abnormal molecular signatures of inflammation, energy metabolism, and vesicle biology in human Huntington disease peripheral tissues
Lobanov SV, McAllister B, McDade-Kumar M, Landwehrmeyer GB, Orth M, Rosser AE, REGISTRY Investigators of the European Huntington’s disease network, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group, Lee JM, MacDonald ME, Gusella JF, Long JD, Ryten M, Williams NM, Holmans P, Massey TH, Jones L
Huntington's disease age at motor onset is modified by the tandem hexamer repeat in TCERG1
Subramaniam S
Striatal induction and spread of the Huntington's disease protein: A novel rhes route
Fodale V, Pintauro R, Daldin M, Spiezia MC, Macdonald D, Bresciani A
Quantifying huntingtin protein in human cerebrospinal fluid using a novel polyglutamine length-independent assay
Ladduwahetty T, Lee MR, Maillard MC, Cachope R, Todd D, Barnes M, Beaumont V, Chauhan A, Gallati C, Haughan AF, Kempf G, Luckhurst CA, Matthews K, McAllister G, Mitchell P, Patel H, Rose M, Saville-Stones E, Steinbacher S, Stott AJ, Thatcher E, Tierney J, Urbonas L, Munoz-Sanjuan I, Dominguez C
Identification of a potent, selective, and brain-penetrant rho kinase inhibitor and its activity in a mouse model of Huntington's disease
Paul BD, Sbodio JI, Snyder SH
Mutant huntingtin derails cysteine metabolism in Huntington's disease at both transcriptional and post-translational levels
Achenbach J, Saft C, Faissner S, Ellrichmann G
Positive effect of immunomodulatory therapies on disease progression in Huntington's disease? Data from a real-world cohort
Xu S, Li G, Ye X, Chen D, Chen Z, Xu Z, Daniele M, Tambone S, Ceccacci A, Tomei L, Ye L, Yu Y, Solbach A, Farmer SM, Stimming EF, McAllister G, Marchionini DM, Zhang S
HAP40 is a conserved central regulator of Huntingtin and a potential modulator of Huntington's disease pathogenesis
Vignone D, Gonzalez Paz O, Fini I, Cellucci A, Auciello G, Battista MR, Gloaguen I, Fortuni S, Cariulo C, Khetarpal V, Dominguez C, Muñoz-Sanjuán I, Di Marco A
Modelling the human blood-brain barrier in Huntington disease
Dawson J, Baine-Savanhu FK, Ciosi M, Maxwell A, Monckton DG, Krause A
A probable cis-acting genetic modifier of Huntington disease frequent in individuals with African ancestry
Reasoner EE, van der Plas E, Al-Kaylani HM, Langbehn DR, Conrad AL, Schultz JL, Epping EA, Magnotta VA, Nopoulos PC
Behavioral features in child and adolescent huntingtin gene-mutation carriers
Byrne LM, Schultz JL, Rodrigues FB, van der Plas E, Langbehn D, Nopoulos PC, Wild EJ
Neurofilament light protein as a potential blood biomarker for Huntington's disease in children
Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, Muñoz-Sanjuan I, Sampaio C, Rosser AE, Leavitt BR
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities
Tabrizi SJ, Schobel S, Gantman EC, Mansbach A, Borowsky B, Konstantinova P, Mestre TA, Panagoulias J, Ross CA, Zauderer M, Mullin AP, Romero K, Sivakumaran S, Turner EC, Long JD, Sampaio C, Huntington’s Disease Regulatory Science Consortium (HD-RSC)
A biological classification of Huntington's disease: the Integrated Staging System
Nazarov S, Chiki A, Boudeffa D, Lashuel HA
Structural basis of huntingtin fibril polymorphism revealed by cryogenic electron microscopy of exon 1 HTT fibrils
Medaglia JD, Erickson BA, Pustina D, Kelkar AS, DeMarco AT, Dickens JV, Turkeltaub PE
Simulated attack reveals how lesions affect network properties in poststroke aphasia
Warner JH, Long JD, Mills JA, Langbehn DR, Ware J, Mohan A, Sampaio C
Standardizing the CAP score in Huntington's disease by predicting age-at-onset
Reasoner EE, van der Plas E, Langbehn DR, Conrad AL, Koscik TR, Epping EA, Magnotta VA, Nopoulos PC
Cortical features in child and adolescent carriers of mutant huntingtin (mHTT)
J Huntingtons Dis
June 3, 2022
11 (2) :173-178
11 (2) :173-178
PMID: 35275555
PMCID: 9177765
DOI: 10.3233/JHD-210512
Turner EC, Gantman EC, Sampaio C, Sivakumaran S
Huntington's Disease Regulatory Science Consortium: accelerating medical product development
Exuzides A, To TM, Abbass IM, Ta JT, Patel AM, Surinach A, Fuller RLM, Luo J
Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population
Rosser AE, Busse ME, Gray WP, Aron Badin R, Perrier AL, Wheelock V, Cozzi E, Perpiña Martin U, Salado-Manzano C, Mills LJ, Drew C, Goldman SA, Canals JM, Thompson LM
Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder
Bertoglio D, Verhaeghe J, Wyffels L, Miranda A, Stroobants S, Mrzljak L, Dominguez C, Skinbjerg M, Bard J, Liu L, Munoz-Sanjuan I, Staelens S
Synaptic vesicle glycoprotein 2A is affected in the CNS of Huntington's Disease mice and post-mortem human HD brain
Shin JW, Shin A, Park SS, Lee JM
Haplotype-specific insertion-deletion variations for allele-specific targeting in Huntington's disease
Tan B, Shishegar R, Fornito A, Poudel G, Georgiou-Karistianis N
Longitudinal mapping of cortical surface changes in Huntington's disease
Lee JM, Huang Y, Orth M, Gillis T, Siciliano J, Hong E, Mysore JS, Lucente D, Wheeler VC, Seong IS, McLean ZL, Mills JA, McAllister B, Lobanov SV, Massey TH, Ciosi M, Landwehrmeyer GB, Paulsen JS, Dorsey ER, Shoulson I, Sampaio C, Monckton DG, Kwak S, Holmans P, Jones L, MacDonald ME, Long JD, Gusella JF
Genetic modifiers of Huntington disease differentially influence motor and cognitive domains
Barbé L, Finkbeiner S
Genetic and epigenetic interplay define disease onset and severity in repeat diseases
Langbehn DR, Fine EM, Meier A, Hersch S
Utility of the Huntington's disease prognostic index score for a perimanifest clinical trial